Pretomanid is a nitroimidazooxazine antibiotic primarily indicated for the treatment of specific forms of multi-drug-resistant tuberculosis affecting the lungs, often used in combination therapy. This… Read more
![Chemical structure of (6S)-6-[3-Methyl-4-(trifluoromethoxy)benzyl]oxy-2-nitro-6,7-dihydro-5H-imidazol[2,1-b][1,3]oxazine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2151045-16-6-6S-6-3-Methyl-4-trifluoromethoxybenzyloxy-2-nitro-67-dihydro-5H-imidazol21-b13oxazine.png&w=3840&q=75)
![Chemical structure of (6s, 6's)-6,6'-(4-(Trifluoromethoxy)-1,3-phenylene)bis(methylene)bis(oxy)bis(2-nitro-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine)](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F6s-6s-66-4-Trifluoromethoxy-13-phenylenebismethylenebisoxybis2-nitro-67-dihydro-5h-imidazo21-b13oxazine.png&w=3840&q=75)
![Chemical structure of (R)-(6-Nitro-2,3-dihydroimidazo[2,1-b]oxazol-3-yl)methanol](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FR-6-Nitro-23-dihydroimidazo21-boxazol-3-ylmethanol.png&w=3840&q=75)
![Chemical structure of (R)-2-Nitro-6-((4-(trifluoromethoxy)benzyl)oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1105708-11-9-R-2-Nitro-6-4-trifluoromethoxybenzyloxy-67-dihydro-5H-imidazo21-b13oxazine.png&w=3840&q=75)
![Chemical structure of (R)-8-Nitro-3-((4-(trifluoromethoxy)benzyl)oxy)-3,4-dihydro-2H-imidazo[5,1-b][1,3]oxazine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FR-8-Nitro-3-4-trifluoromethoxybenzyloxy-34-dihydro-2H-imidazo51-b13oxazine.png&w=3840&q=75)
![Chemical structure of (S)-2-Nitro-6-((2-(trifluoromethoxy)benzyl)oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1353753-55-5-S-2-Nitro-6-2-trifluoromethoxybenzyloxy-67-dihydro-5H-imidazo21-b13oxazine.png&w=3840&q=75)
![Chemical structure of (S)-2-Nitro-6-((3-(trifluoromethoxy)benzyl)oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1353753-57-7-S-2-Nitro-6-3-trifluoromethoxybenzyloxy-67-dihydro-5H-imidazo21-b13oxazine.png&w=3840&q=75)




![Chemical structure of (S)-3-Nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl pivalate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FS-3-Nitro-67-dihydro-5H-imidazo21-b13oxazin-6-yl-pivalate.png&w=3840&q=75)
![Chemical structure of (S)-3-Nitro-6-((4-(trifluoromethoxy)benzyl)oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1131004-99-3-S-3-Nitro-6-4-trifluoromethoxybenzyloxy-67-dihydro-5H-imidazo21-b13oxazine.png&w=3840&q=75)







![Chemical structure of 6-Nitro-2-(((4-(trifluoromethoxy)benzyl)oxy)methyl)-2,3-dihydroimidazo[2,1-b]oxazole](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1263187-37-6-6-Nitro-2-4-trifluoromethoxybenzyloxymethyl-23-dihydroimidazo21-boxazole.png&w=3840&q=75)
![Chemical structure of 6-Nitro-3-((((R)-tetrahydro-2H-pyran-2-yl)oxy)methyl)-2,3-dihydroimidazo[2,1-b]oxazole](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F6-Nitro-3-R-tetrahydro-2H-pyran-2-yloxymethyl-23-dihydroimidazo21-boxazole.png&w=3840&q=75)


Pretomanid is a nitroimidazooxazine antibiotic primarily indicated for the treatment of specific forms of multi-drug-resistant tuberculosis affecting the lungs, often used in combination therapy. This category provides a comprehensive selection of high-quality reference standards essential for pharmaceutical analysis. Analytical laboratories utilize these materials for rigorous quality control, method validation, and impurity profiling. The collection encompasses the active pharmaceutical ingredient alongside its pharmacopeial and non-pharmacopeial impurities, as well as various degradation products that may arise during synthesis or storage. Furthermore, stable isotope labelled compounds are available to support precise quantification in complex biological matrices, facilitating accurate mass spectrometry-based assays. By offering these well-characterized reference compounds, this catalogue enables researchers and quality control professionals to maintain compliance with safety standards and ensure the consistency of therapeutic formulations throughout the drug development lifecycle.